Latest News
From the Journals
Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
Subsequent risk of estrogen receptor–negative breast cancer was elevated irrespective of the type of therapy given for Hodgkin lymphoma.
From the Journals
Contaminated graft causes infection in ALL patient
The infection was confirmed using pulsed-field gel electrophoresis.
From the Journals
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
Patients who received letrozole after debulking surgery and platinum-based chemotherapy had a significantly prolonged recurrence-free interval.
From the Journals
Frontline brentuximab vedotin improved Hodgkin lymphoma outcomes
The study looked at the addition of brentuximab vedotin to chemotherapy in previously untreated patients with stage III or IV classic Hodgkin...
From the Journals
Retroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinoma
In a secondary analysis of the ASSURE adjuvant trial, there was no relative improvement in overall survival for lymphadenectomy in high-risk RCC...
From the Journals
Neoadjuvant dabrafenib and trametinib improves event-free survival in resectable melanoma
The phase 2 trial was closed early due to the difference in event-free survival favoring the neoadjuvant approach.
Conference Coverage
Pembrolizumab plus SBRT shows promise for advanced solid tumors
Pembrolizumab immunotherapy with multi-site SBRT appears to be a safe and effective treatment in patients with advanced solid tumors.
Conference Coverage
VIDEO: COMPASS shows stroke-clot aspiration noninferior to retrieval
LOS ANGELES – An initial strategy of clot aspiration was noninferior to initial clot removal with a stent retriever in a multicenter randomized...
Conference Coverage
Experimental PD-1/PARP inhibitor combo shows promise in solid tumors
An experimental PD-1 inhibitor/PARP 1/2 inhibitor combination therapy shows promise for the treatment of advanced solid tumors.
Conference Coverage
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
With median follow-up of 13.4 months, 55% of metastatic CRC patients had a response to the combination of nivolumab and ipilimumab in the...
News
FDA approves lutetium Lu 177 dotatate for GEP-NETs
This is the first approval of a radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors.